Sandrine Lavau‐Denès

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 232 citations

Medicine, Oncology, Chemotherapy +14

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 128 citations

Medicine, Oncology, Breast Oncology +9

Nutritional Advice in Older Patients at Risk of Malnutrition during Treatment for Chemotherapy: A Two-Year Randomized Controlled Trial

Isabelle Bourdel‐Marchasson, C. Blanc-Bisson, A. Doussau et al. · PLoS ONE · 2014 · 127 citations · Full text

Agriculture, Nutrition, Oncology +17

Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial

Patricia Pautier, Anne Floquet, Christine Chevreau et al. · The Lancet Oncology · 2015 · 114 citations

Medicine, Gynecology, Oncology +7

Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001–02)

Thomas Aparicio, Sandrine Lavau‐Denès, Jean–Marc Phelip et al. · Annals of Oncology · 2015 · 111 citations · Full text

Medicine, Oncology, Pharmacology +8